Single Ascending and Multiple Ascending Dose Study of LCA-0061

Key Inclusion Criteria: Part A (SAD) and Part B (MAD)

• Must provide written consent for participation
• Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2 (inclusive) and body weight ≥ 50kg at screening
• Have elevated serum IgE at screening
• Female participants of childbearing potential or male participants capable of fathering a child must be willing to use highly effective methods of contraception throughout the study and for at least 30 days after the last dose of the investigational product.

Part A Only

1.Must be otherwise healthy with history of atopy defined as one or more of the following: history of positive skin tests to common allergens, allergic conjunctivitis, food allergy, atopic dermatitis, urticaria

Part B Only

• Be otherwise healthy with history of peanut allergy
• Elevated peanut-specific serum IgE within 6 months of screening
• Have positive skin prick test (SPT) to peanuts at screening

Key Exclusion Criteria: Part A and B

• Pregnant or lactating
• History of clinically relevant underlying comorbidities including:

• chronic obstructive pulmonary disease
• myocardial infarction
• chronic heart failure or unstable angina pectoris
• hyperlipidemia
• liver disease or known hepatic or biliary abnormalities [except Gilbert's disease or asymptomatic gallstones]
• autoimmune or connective tissue disease
• chronic inflammatory disease
• persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals
• poorly controlled atopic dermatitis requiring treatment with phototherapy, systemic immunosuppressants, or immunomodulators
• Poorly controlled asthma
• poorly controlled hypertension
• clinically significant abnormal electrocardiogram or laboratory tests (hematology, clinical chemistries, liver function tests, lipid panel, serology, or urinalysis) at screening
• Currently receiving immunotherapy for food allergies
• Use of nicotine containing products (excluding nicotine patches or gum for smoking cessation) within 6 months prior to screening.
• Positive test for alcohol or illicit drugs at screening or prior to dosing.
• Other conditions or concomitant medications that are excluded by the protocol, or in the opinion of the investigator, or sponsor representative, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.